Cochrane · systematic review · CD013594
Treating progressive disseminated histoplasmosis in people living with HIV
Murray, M, Hine, P · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 25%Low 2 · 50%Moderate 0 · 0%High 1 · 25%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Induction: liposomal amphotericin compared with amphotericin deoxycholate
Population: adults with HIV and progressive disseminated histoplasmosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical success Induction: liposomal amphotericin vs amphotericin deoxycholate | RR 1.46 [1.01, 2.11] | 1 study · 80 participants | Low Downgraded: imprecision |
Death Induction: liposomal amphotericin vs amphotericin deoxycholate | RR 0.15 [0.02, 1.38] | 1 study · 77 participants | Low Downgraded: imprecision |
Safety outcomes: nephrotoxicity Induction: liposomal amphotericin vs amphotericin deoxycholate | RR 0.25 [0.09, 0.67] | 1 study · 77 participants | High |
Safety outcomes: drug discontinuation Induction: liposomal amphotericin vs amphotericin deoxycholate | RR 0.23 [0.02, 2.38] | 1 study · 77 participants | Very low Downgraded: risk of bias, imprecision |